Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates Nutritionals, Therapeutics and IT to advance interventions for preventing and treating autoimmune and metabolic diseases.
Through significant NIH funding (+$12M) in grants, the company holds numerous US and international patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with over 120 mouse studies with >1000 mice resulting in 9 peer reviewed publications elucidating the pathway and showing the compounds to be both safe and effective. Currently the company is expanding rapidly to support additional pre-clinical efficacy studies with the goal of submitting an investigational new drug (IND) application to the Food and Drug Administration (FDA) within 12-18 months.
The BTI team has ample experience establishing pig models of infectious and immune-mediated diseases, including inflammatory bowel disease (IBD) and infections caused by enteric or respiratory pathogens. As opposed to mice, pigs offer a physiological composition more comparable to humans. Their mucosal immune system is an ideal model for studying the complexity of the human immune system and how it responds to inflammation, infection and injury. Preclinical studies using pigs lay the groundwork for an informed design of human clinical trials.
Our BTI facilities and animals:
Active monitoring post-challenge is performed to ensure the well-being of the animals and provide an assessment of disease activity progression throughout the duration of the experiment. Peripheral blood collection is performed on a regular basis as a means of analyzing the time course of an infection. Execution of specific expected goals is met with superior efficiency in a timely manner while maintaining detailed attention to our animals and data.
What BTI can offer
BTI can offer pig projects with the following disease models:
To identify genes that are differentially expressed between experimental contrasts, we possess an automated pipeline based off Illumina Hiseq sequencing of transcriptomes. The pipeline integrates short read alignment with interval calculations optimized for mammalian genomes, normalization, aggregation and statistical testing.
Our RNA sequencing pipeline offers analyses on:
Understanding the immune system’s dynamics requires a coherent picture of the of a complex interplay between inflammatory and regulatory immune responses at the cellular and molecular level. Computational modeling can be used to synthesize, organize and integrate diverse types of data and theoretical frameworks to help advance or rule out drug candidates in the pipeline.
BTI has a track record on computational modeling and immunoinformatics, and this knowledge is used to guide and develop computational models for our partners and clients.
Our areas of computational modeling expertise a ranges from molecular to intracellular to tissue-level modeling. We have developed automated pipelines to:
Our areas of expertise are:
Biotherapeutics Inc. offers a broad array of preclinical services in mouse, rats and pigs for product testing, mechanism of action validation studies, and hypothesis–driven and hypothesis-generating in vivo experimentation. All our preclinical animal models are set up in Institutional Animal Care and Use Committee (IACUC)-approved facilities. Animals are housed in a state-of-art facility that can accommodate large projects as well as both BL-1 and BL-2 experiments.
BTI offers pre-clinical efficacy animals models of the following diseases:
Biotherapeutics Inc. (BTI) has not received any reviews.
Biotherapeutics Inc. (BTI) has not received any endorsements.